약학회지
YAKHAK HOEJI
ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 5.

Table. 5.

Clinical impacts on drug-drug interactions

Perpetrator drugs Victim drugs Clinical drug-drug interactive outcomes
Norvir Voriconazole Increased blood concentration
Diltiazem Warfarin Lack of anticoagulation effect.
Pravastatin, tolbutamide, hydrochlorothiazide No significantly different pharmacokinetic profile
Midefradil beta-blockers Heart shock
Simvastatin Myopathy appears in hypertensive patients
Fluoxetine Thioridazine Severe ventricular arrhythmia due to elevated blood levels
Phenytoin, carbamazepine Increased blood concentration and toxicity
Haloperidol, clozapine Increased blood concentration
Pimozide Prolongation of QT intervals
Alprazolam Increased blood concentration and psychomotor function is reduced
Warfarin Side effects of anticoagulants, including increased bleeding
Ketoconazole, erythromycin Terfenadine Severe heart toxicity
Clarithromycin Theophylline Increased Cmax and AUC (approx. 20%)
Carbamazepine Increased blood concentration
Ritonavir Need to reduce the dose of clarithromycin in patients with renal impairment
Oral anticoagulants Increased effect of anticoagulants
Digoxin Digitalis toxicity
Cyclosporine Diclofenac, methotrexate Increased AUC
Colchicine, statins, prednisolone Decreased CL
Digoxin Digitalis toxicity
Colchicine Myopathy and neuropathy in patients with renal failure
Sirolimus Increased blood concentration in patients with renal failure
Silybin Indinavir Decreased AUC and blood concentration level (9~25%)
Yakhak Hoeji 2020;64:8-20 https://doi.org/10.17480/psk.2020.64.1.8
© 2020 Yakhak Hoeji